Structure based virtual screening to identify selective phosphodiesterase 4B inhibitors.

Area of Science:

• Medicinal Chemistry
• Computational Chemistry
• Pharmacology

Background:

• Phosphodiesterase 4 (PDE4) is a key enzyme targeted for treating inflammatory respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD).
• Non-selective PDE4 inhibitors cause dose-limiting adverse effects; thus, selective PDE4B inhibitors are highly desirable to improve therapeutic outcomes and patient tolerance.

Purpose of the Study:

• To develop selective PDE4B inhibitors by employing ligand-based pharmacophore modeling and molecular docking.
• To identify novel compounds with potent and selective inhibitory activity against PDE4B, aiming to reduce side effects associated with non-selective PDE4 inhibition.

Main Methods:

• Generated pharmacophore hypotheses for PDE4B and PDE4D using the HypoGen algorithm.
• Validated pharmacophore models were utilized for virtual screening to identify potential selective PDE4B inhibitors.
• Molecular docking and drug likeness assessments were performed on screened hits, followed by in vitro validation of selected compounds.

Main Results:

• The best PDE4B pharmacophore model featured one hydrogen-bond acceptor and two aromatic ring features.
• Virtual screening identified several potential inhibitors, which were further refined through docking and drug likeness analysis.
• Six of the ten purchased compounds demonstrated potent and selective PDE4B inhibition in vitro, with IC50 values ranging from 2 to 378 nM.

Conclusions:

• Ligand-based pharmacophore modeling and molecular docking are effective strategies for discovering selective PDE4B inhibitors.
• The identified compounds represent promising leads for developing novel therapeutics for asthma and COPD with improved safety profiles.